Armata Pharmaceuticals, Inc.
ARMP · AMEX
Market closed$4.51$0.750000 (+19.95%)After hours $4.32 · -4.32%
Key statistics
Previous close$3.76
Open$3.81
Day high$4.55
Day low$3.81
52-week high$16.34
52-week low$2.32
Market cap165.57M
Volume269.84K
Average volume132.10K
P/E ratio-1.02
Forward P/E—
EPS-4.41
Dividend yield0.00%
Market context
Why it moved
Armata Pharmaceuticals (ARMP) surged sharply today, likely driven by heightened investor interest in biodefense and pharmaceutical companies amid the rapidly escalating U.S.-Iran military conflict, which has intensified demand for defense-related and medical countermeasure stocks.
What is happening
Recent company-specific developments and publisher coverage.
Seeking Alpha · July 18, 2026Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP)Investing.com · July 13, 2026Armata receives FDA agreement on pediatric study plan for AP-SA02PR Newswire · June 23, 2026Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02PR Newswire · May 13, 2026Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdatePR Newswire · May 7, 2026Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02Stock Titan · April 27, 2026Pfizer leader tied to Paxlovid launch joins Armata boardPR Newswire · March 25, 2026Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsStock Titan · January 13, 2026First phage therapy for staph bloodstream infections heads to Phase 3 Mt Newswire · July 13, 2026Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02 Benzinga · July 13, 2026Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan Mt Newswire · June 23, 2026Armata Pharmaceuticals Receives Additional $2.5 Million in Funding From US Department of Defense Benzinga · June 23, 2026Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command Benzinga · May 13, 2026Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY Benzinga · May 7, 2026Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections Benzinga · May 4, 2026Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio Benzinga · March 25, 2026Armata Pharmaceuticals Q4 EPS $(3.43) Misses $(0.28) Estimate, Sales $1.085M Beat $750.000K Estimate